Novanta Inc. (NASDAQ:NOVT) Q3 2023 Earnings Call Transcript
Novanta Inc. (NASDAQ:NOVT) Q3 2023 Earnings Call Transcript November 7, 2023
Novanta Inc. beats earnings expectations. Reported EPS is $0.85, expectations were $0.74.
Operator: Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Incorporated 2023 Third Quarter Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Ray Nash, Corporate Finance Leader for Novanta. Please go ahead.
Ray Nash: Thank you very much. Good morning and welcome to Novanta's third quarter 2023 earnings conference call. I am Ray Nash, Corporate Finance Leader of Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra; and our Chief Financial Officer, Robert Buckley. If you've not received a copy of our earnings press release issued today, you may obtain it from the Investor Relations section of our website at www.novanta.com. Please note this call is being webcast live and will be archived on our website shortly after the call. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued earlier today and also those in our SEC filings.
We may make some comments today, both in our prepared remarks and in our responses to questions that may include forward-looking statements. These involve inherent assumptions with known and unknown risks and other factors that could cause our future results to differ materially from our current expectations. Any forward-looking statements made today represent our views only as of this time. We disclaim any obligation to update forward-looking statements in the future, even if our estimates change. So you should not rely on any of these forward-looking statements as representing our views as of any time after this call. During this call, we will be referring to certain non-GAAP financial measures. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available as an attachment to our earnings press release.
To the extent that we use non-GAAP financial measures during this call that are not reconciled to GAAP measures in the earnings press release, we will provide reconciliations promptly on the Investor Relations section of our website after this call. I am now pleased to introduce the Chair and Chief Executive Officer of Novanta, Matthijs Glastra.
Matthijs Glastra: Thank you, Ray. Good morning, everybody, and thanks for joining our call. Novanta had a solid third quarter with strong operating performance, delivering profit and cash flow above our expectations. Our revenue was in line with previously issued guidance. In the quarter, we delivered $222 million in revenue, representing a 1% year-over-year revenue decline on a reported basis, a 3% decline on an organic basis. Excluding microelectronic applications, our growth in the quarter was up low single digits. We recorded gross margins of 47% in the quarter and an adjusted EBITDA margin of nearly 24%. In addition, our cash flow was up over 2x the prior year and at more than 175% conversion to net income. This operating performance reflects excellent execution by our teams in an increasingly challenging macroeconomic environment.
The Novanta business model, with diversified exposure to secular high-growth markets has proven resilient under multiple geopolitical and macroeconomic scenarios. Our proprietary products and technologies are well positioned in medical and advanced industrial applications with long-term secular tailwinds such as robotics and automation, healthcare productivity and precision medicine. Medical applications now make up nearly 60% of our sales versus single-digit percentage of sales a decade ago, which we believe provides Novanta with greater resilience during fluctuating macroeconomic conditions. We feel that our strong customer relationship with the leading OEMs in these medical and advanced industrial applications, the strength and diversification of our portfolio and our sticky business model will allow Novanta to deliver and drive better performance through the economic cycles.
In the third quarter, the Novanta team has made excellent progress in bringing down lead times to our customers. The consequence of this change is that customers do not need to place long-term orders anymore, resulting in a book-to-bill of 0.8, which was in line with our expectations. However, this change in lead times improves customer satisfaction and allows the business to better trend with end-market demand dynamics. Speaking to the business environment more broadly. In the past couple of months, we start to see more caution in some of our customers' ordering behavior. With the rapid rise in interest rates in the last months, continued weakness in China, and expanding geopolitical unrest, our OEM customers have seen their customers slow down ordering, particularly in industrial and more recently, some life science applications.
While this has clearly been evident in the global purchasing managers indices for industrial spending, the rapid rise in interest rates has caused other capital equipment markets to be more cautious as well, deferring purchases until the new year. Given the strong secular growth drivers behind our markets and our customers' engagement on innovation, we see these current dynamics as temporary, despite the impact on the fourth quarter. Robert will discuss these dynamics in more detail when he covers guidance. It is important to note that the Novanta playbook and business model have demonstrated ability to effectively navigate short-term headwinds. We've accomplished this, while at the same time staying focused on making investments that expand our presence in secular high-growth markets.
We continue to see active engagement and urgency with our customers to ensure their new product launches are a success. As a result, we're seeing a broad new product super-cycle entering late in 2024 and in 2025 and beyond, with key drivers including smoke evacuation insufflation, robotic surgery, next-generation lithography, laser beam steering for advanced material processing such as laser additive manufacturing and micromachining, robotic end effector sensors and mobile robotics. Given our sticky business model in these long-lifecycle growth applications, we strongly believe the mid and long-term outlook of our business, our end markets and Novanta organic growth algorithm to be intact. Looking back to the third quarter, the broader end market seems we're, that medical markets continue to be strong, industrial markets are decelerating in line with the PMI indices and interest rate environment, and microelectronics is bottoming at a low level.
Excluding microelectronics, Novanta revenue growth would have been up low single digits year-over-year in the quarter. Going into more detail, sales to medical markets remained strong in the quarter, growing 12% versus the prior year and making up approximately 57% of total Novanta sales. During the quarter, we saw increased shipments to many of our medical OEM customers with noteworthy strength in minimally invasive surgery equipment and consumables, surgical robotics, DNA sequencing, and integrated operating room equipment. These categories all saw double-digit growth in sales year-over-year, where long-term secular growth is driven by patient surgical procedure growth rates and advancements in biopharma technologies, including next-generation DNA sequencing.
We continue to find new growth opportunities in our medical markets. For example, we see opportunities to expand our presence in DNA sequencing to the broader precision medicine market, including spatial biology, multiomics and other clinical life science applications, by combining the proprietary Novanta technologies into unique solutions for our customers. In doing so, we believe we can help our customers win by shortening their time to market and enhancing their differentiation. In addition, we continue to remain very excited about the long-term secular growth in minimally and robotic surgery markets, with Novanta continuing to win with our next-generation smoke evacuation, endoscopic pump technologies, precision motion drives, and our force torque sensors.
Turning to advanced industrial markets. Our sales in the third quarter, excluding microelectronic applications were down 6% year-over-year and made up approximately 36% of total Novanta sales. This sales decline was slightly more than we expected due to the rapid rise in interest rates and continued weakness in China impacting the industrial robotics and automotive sectors. While these trends are expected to worsen somewhat in the fourth quarter, customers remain very engaged and are using the slowdown to catch up on next-generation innovations. As a reminder, Novanta plays in advanced industrial applications with mid to single-digit growth driven by secular growth trends such as Industry 4.0, robotics and automation, and precision manufacturing.
Finally, our microelectronics markets represented less than 8% of sales in the quarter. The dynamics are roughly the same as we said in our last call. In the quarter, we saw nearly a 40% decline year-over-year from the cyclical downturn in this market, particularly driven by our PCBA via hole drilling business, which is now run rating at just a couple of million dollars of revenue per quarter, which is immaterial to overall company results. We estimate that the overall drop in the microelectronics market will be a 400 basis point headwind on total Novanta sales growth for the full year. Again, excluding microelectronics, Novanta revenue in the third quarter will be up low single-digit year-over-year. As we look out into 2024 and 2025, we do, however, remain excited that the composition of our exposure to this market will be a more secular growing and less volatile business.
As we mentioned in prior calls, we believe our exposure to next-generation lithography will continue to grow, positioning us well to capitalize on a less cyclical element of the industry, with at least a decade's worth of growth still ahead of us. From a regional perspective. In the third quarter, sales to North America grew 11% year-over-year and sales in Europe declined by 2%, which reflects the challenging macroeconomic conditions in this region and its connections with the China market. Sales in China, which represented about 7% of overall sales declined 35% year-over-year, which was caused by the decline in microelectronics revenue, the industrial robotics pause, and overall microeconomic uncertainty in China right now. These regional trends are expected to continue in the fourth quarter.
Now, let me touch on some of Novanta's strategic growth metrics. For our design wins in the quarter, we saw significant progress with numerous large customer wins. We had another large win with the leading minimally invasive surgery OEM, where their platform will now incorporate our next-generation smoke evacuation insufflator technology. Based on our design wins in this market, we expect Novanta's technology to be the standard of care for minimally invasive surgeries for at least the next decade. In addition, in the quarter, our medical solutions segment also had a large design with a leading player in the integrated operating room market, where a video and data management product will be integrated into a new platform launching in 2025. Finally, this business closed a design win within the sports medicine and arthroscopy market with our proprietary pump technology, which is also expected to launch in late 2025 and expands our market share in this application.
In the precision medicine and manufacturing, and robotics and automation segments, we also had several exciting wins. We continue to make significant progress expanding our exposure to next-generation lithography equipment, an area which has a decade long growth outlook. Given recent customer announcement, growth in this application is now expected in late 2024, which will accelerate in 2025. We're also very excited by recent design wins in our force torque sensor product line, which enables a sense of end of arm touch for robots in industrial and medical applications. After significant effort, this business has started shipping into the medical space, representing a significant milestone in the realization of a critical value driver for the ATI acquisition.
In addition, within our robotics and automation segment, we recently won a new multi-million dollar project with a leading robotics player who is planning to integrate our miniaturized high-performance server drives into their next generation of advanced mobile robotics. This opportunity will start to ramp up in 2025. We're excited by the impressive accumulation of customer design wins and our strongest innovation pipeline in a decade. We remain highly focused on executing our new product super cycle starting late in 2024 and into 2025, and reiterate with confidence our overall long-term growth framework of consistent mid to high single-digit organic growth through the business cycles. Next, our Vitality Index in the third quarter was about mid-teens percentage of sales, which is roughly the same as prior quarter, and in line with our expectations.
Our new product pipeline is geared towards intelligent subsystems in applications such as minimally invasive surgery, robotic surgery, next-generation precision medicine, laser beam steering for micromachining, electric vehicle, robotic tool changers, precision motion solutions for mobile robotics, and warehouse automation. After our next-generation products start launching with customers in late 2024, we expect our Vitality Index to rebound to above 20%, driving sustained growth in secular growth markets. Moving on, I'm proud to say, how our teams are embedding the Novanta growth system, or NGS into the way we work. During the third quarter, we held the President's Kaizen week in our Medical Solutions segment, bringing together dozens of our senior leaders and many other team members to focus on process improvements and problem-solving in critical areas for the business, such as the ramp of manufacturing of our in house medical consumable products at our new Czech Republic factory.
We're also using NGS project management tools to compress our time to market of NPI launches and compensate for delays due to supply chain shortages in the last 18 months. A critical tool we're deploying is 80-20 portfolio management. We're using this approach to rationalize a portfolio, reducing our exposure to products that are commoditizing or nearing end of life. We're taking these actions to decrease complexity, improve profitability in light of near-term market conditions, and to allow the teams to focus more on ramping the new -- the multiple new products that will be coming online late in 2024. Overall, these tools in kaizen events are becoming a critical part of our NGS deployment, our culture and demonstrating our commitment to continuous improvement and our ability to solve complicated problems that benefit our operating performance as well as improve customer satisfaction.
Next, I'd like to give you a brief update on Novanta's acquisition activities. Acquisitions remain Novanta's top priority for capital allocation, and you should expect this to continue to be a critical part of our growth strategy. We have multiple active conversations underway today and would expect at least one of these materializing before year-end. You can expect us to lean in on expanding our presence in the megatrends I talked about earlier. We view disruptive macroeconomic environments as an opportunity to take advantage for M&A activity as sellers change their expectations in light of higher interest rate environment. As such, we expect to be an active acquirer in this environment. In conclusion, we had a solid third quarter with excellent operating performance, delivering profits and cash flow ahead of expectations and sales in line with expectations.
Despite the short-term macro outlook, we believe Novanta's long-term strategic positioning continues to be extremely strong and we're staying the course on executing our strategy and capital deployment model. With that, I will turn the call over to Robert to provide more details on operations and financial performance. Robert?
Robert Buckley: Thank you, Matthijs, and good morning everyone. Our third quarter non-GAAP adjusted gross profit was $105 million, or 47% adjusted gross margin, compared to $102 million, or 46% adjusted gross margin in the third quarter of 2022. For the quarter, adjusted gross margins were up year-over-year by over 160 basis points and up sequentially by 30 basis points. This outcome was better than our expectations and represents strong execution by our teams to achieve this result. Our continued progress with gross margin expansion in 2023 is being largely driven by the deployment and successful adoption of the Novanta NGS productivity tools in our factories. The 47% gross margin puts us on a solid track to achieving our full-year goal of expanding gross margins by 100 basis points.
Moving on to the operating expenses. R&D expenses were roughly $22 million, or approximately 10% of sales. Third quarter SG&A expenses were $40 million, or roughly 18% of sales. Overall operating expenses as a percent of sales were flat year-over-year in the quarter. While we continue to invest in new product innovations and prepare for the launch of multiple new product platforms, the organization also demonstrates strong cost management. Adjusted EBITDA was approximately $52 million in the third quarter of 2023, or 23.6% adjusted gross -- adjusted EBITDA margin, versus $49 million in the prior year. On the tax front, our non-GAAP tax rate for the third quarter of 2023 was 15%. This differed from the statutory rate due to jurisdictional mix of income and some timing-related tax benefits.
Our non-GAAP adjusted earnings per share was $0.85 in the quarter compared to $0.81 in the third quarter of 2022. Third quarter operating cash flow was approximately $45 million, which is up greater than 200% versus the prior year. We are pleased with this result, which results in strong profitability in the quarter and some progress in reducing our inventory balances. We ended the quarter with gross debt of $357 million versus gross debt of $413 million in the second quarter of 2023, and our gross leverage ratio was 1.8 times. Our net debt was $281 million, putting the company in a great position to fund further acquisitions. Turning to backlog and bookings. Our team again made great progress reducing our past due backlog to customers by more than 24% sequentially, while still ending with a backlog of $536 million, which is nearly 2x pre-pandemic coverage levels.
Our remaining past-due backlog is now immaterial and so we have started to pivot to reducing lead times and on-time shipments of our new orders to historical levels. Our book-to-bill in the third quarter was 0.8, which is in line with our expectations. I'll now turn to an update about the performance of our operating segments. First, I'll speak to the Precision Medicine and Manufacturing segment for the third quarter of 2023. This segment demonstrated strong financial performance overall with strong gross margins and strong EBITDA margins despite weaker-than-expected revenue growth. While this segment delivered 1% year-over-year growth, this was lower than we expected as industrial customers delayed purchases due to the higher interest rate environment and new geopolitical disruptions.
The book-to-bill was 0.72x in the third quarter, which reflects continued normalization of lead times as customers adjusted their level backlog coverage to pre-pandemic levels and some softening of demand from life science, precision medicine end markets, which also experienced the impact of higher interest rate environment. Within precision medicine, new product revenue stayed greater at 20% of sales in the third quarter. Design wins in the segment were down year-over-year, driven by timing and difficult comparisons as in the last few quarters. Despite this, for the full year of 2023, we still expect solid design win growth in the range of 10% to 20% year-over-year. We're excited about the progress being made with multiple strategic customers.
For example, we recently completed new key milestones to grow our exposure to next-generation lithography applications. These customer opportunities gives us confidence we will continue to see growth in this segment heading into future years. The Precision Medicine and Manufacturing segment adjusted gross margin was nearly 52% in the quarter, which was up 100 basis points -- 180 basis points year-over-year. We are proud of the performance of our manufacturing operation teams, particularly as they embrace and institutionalize the Novanta growth system. Turning to Robotics and Automation segment, this segment experienced a revenue decline of 15% year-over-year, which is in line with our expectations and our prior guidance. This decline continues to be mainly driven by steep year-over-year declines in microelectronics applications, particularly our PCBA mechanical via hole drilling applications, which declined over 70% and is now an immaterial level of sales for the company.
In addition, as discussed in our last call in the quarter, this segment saw an impact from weakness in the sales of industrial robotics, largely caused by China and the slowdowns in the automotive manufacturing. The overall book-to-bill ratio in this segment was 0.79, again driven by the microelectronics decline in industrial demand dynamics in China. Microelectronics experienced a negligible level of bookings in the quarter. On the positive side, our ATI business saw a book-to-bill greater than 1 in the third quarter, indicating that the decline in industrial robotics is stabilizing. New product revenue was roughly 10% of total sales in this segment in the quarter. As a reminder, this ratio is lower than 2022 because the metric now includes new product sales from our ATI business line, which is having a dampening effect on the overall segment ratio.
Adjusted gross margin for Robotics and Automation segment came in at roughly 51%, which was roughly flat sequentially and up year-over-year by 200 basis points. Again, we are proud of the progress our teams were making by adopting the Novanta growth system to drive strong margin performance while reducing lead times, improving on-time delivery and improving product quality despite year-over-year revenue declines. A further testament of their progress, this segment achieved a rare preferred supplier rating from a top five medical customer. Finally, in Medical Solutions, this segment experienced reported revenue growth of 14% year-over-year, which was stronger than our expectations. Growth in this segment continues to be driven by strength in elective surgical procedures as well as our JADAK business line where the business continues to perform well now that supply chain challenges have been mitigated.
The Medical Solutions segment saw a book-to-bill of 0.87 in the third quarter with bookings up 2% year-over-year. The Vitality Index in this segment was reduced versus prior year and is at mid-teens percent of sales level in line with our expectations. As we mentioned in prior earnings call, this is largely driven by our first-generation smoke evacuation insufflator product reaching its four-year milestone. We expect this metric to rebound in 2024 as we launch our second-generation smoke evacuation insufflators and new endoscopic pumps. Design win activity in the segment was very robust in the third quarter despite tough comps in prior year. This was driven by another impressive design win in the minimum invasive surgical space related to our next-generation insufflator technology and an impressive design win with our integrated operating room technology products with a leading OEM in that space.
Overall, our business performed as we expected in the quarter. This is a testament to the high caliber of talent in our business teams and their ability to navigate and work together to deal with numerous challenges despite rapidly changing economic circumstances. We are proud of the team's performance. Now turning to guidance. While we still have historical high backlog coverage heading into a more uncertain demand environment, we are working closely with our customers to schedule shipments in a manner that avoids our customers building inventory and which is in line with their end market demand. We feel this approach avoids any unnecessary revenue volatility in the future and avoids our revenue from being disconnected from end market demand.
This is factored into the fourth quarter revenue guidance and we expect will lead to book-to-bill ratios in the fourth quarter comparable to the third quarter. From an end market perspective, we continue to expect to experience growth in our medical end markets despite temporary weakness materializing in precision medicine and life science end markets due largely to the interest rate environment. Despite these near-term customer deferrals that we expect will manifest in the fourth quarter, remain confident the long-term secular demand in these markets and the medium-term demand we expect from customer launches of new products in the second half of 2024. As an example, we continue to see strong customer demand and urgency for our second-generation smoke evacuation technologies, a new endoscopic pump platform, a new integrated operating room technology platform, and new optical subsystems for customers in the precision medicine market, including spatial genomics and bioprocessing.
Therefore, we continue to invest with confidence that better position ourselves to serve these secular growing markets. In our advanced industrial end markets, representing slightly more than 40% of overall sales, global purchasing manager indices remain below 50, indicating industrial capital spending remains in contraction. We are now lapping the fourth quarter in a row of PMIs falling into contraction territory, led by a cyclical downturn in the microelectronics and macroeconomic weakness in China, starting in the third quarter of 2022. Industrial capital spending slowed more broadly in the third quarter of 2023, following a significant spike in interest rates, particularly in the US, and further weakening in China. As we enter the fourth quarter, the geopolitical environment has worsened, particularly in the Middle East, and industrial spending has slowed further as industrial manufacturing customers have deferred purchases and are still starting to feel the pressure of the spike of interest rates.
While there are signs of capital spending stabilizing by year-end after what will be five quarters of PMIs below 50 and of interest rates stabilizing at these elevated levels, the combination of volatility in the macroeconomic and geopolitical environment and the lead times of our business compels us to revise our fourth quarter financial expectations down from our original expectations and also down sequentially from the third quarter. Starting with revenue guidance. For the fourth quarter of 2023, we expect GAAP revenue in the range of $208 million to $212 million, which represents a revenue decline of approximately 5% on a year-over-year basis. In the full year of 2023, we now expect GAAP revenue in the range of $878 million to $882 million.
This represents low single-digit growth for the full year, which is below our original expectations for the second half of 2023. However, based on deep conversations with our customers, we expect this to be a temporary deferral in demand, which further emphasizes the need to focus and allocate our resources to the secular growing and less cyclical end markets. On a segment level, in the fourth quarter, we expect Precision Medicine and Manufacturing segment revenue to be flat to down 4% organically on a year-over-year basis. While there are aspects of our business doing well, demand deferrals in industrial applications and some life science applications are impacting the segment's growth in the fourth quarter. Although near-term demands remain softer than expected, customer activities, particularly around new product introductions remain active and design win activities continue to accelerate.
Our Robotics and Automation segment is expected to be down 9% to 14% year-over-year in the fourth quarter. The year-over-year decline is mainly driven by the continued pause in industrial robotic spending, particularly in China, and continued weakness in microelectronics. While there are signs that demand is starting to stabilize, the higher interest rate environment needs to further normalize at these elevated levels before demand fully recovers. Finally, our Medical Solutions segment is expected to demonstrate year-over-year revenue growth in the 4% to 6% range in the fourth quarter. While there are more difficult comparisons to the prior year, overall demand in this segment continues to align with global surgical procedural growth rates.
Customers in this segment are working with urgency to accelerate and finalize launches of the second-generation smoke evacuation technology and to focus their product portfolios on their new innovations. Our medical technologies continue to incent strong demand from our customers, resulting in full year 2023 revenue growth in the mid-teens territory. Moving on to overall Novanta's adjusted gross margin. We expect gross margins in the fourth quarter to be approximately 46.5% to 47%. Gross margins in this segment will largely mirror the margins achieved in the third quarter. Increases or decreases per segment will only be based on changes in sales volume. Regardless, overall margins should meet or exceed our full-year expectations of 100 basis point improvement year-over-year.
For the full-year 2023, we now expect adjusted gross margins to be approximately 46.6% to 46.8%, a testament of our team's adoption of the Novanta growth system. Turning to R&D and SG&A expenses, they are expected to be approximately $64 million to $65 million in the fourth quarter. The increase in cost year-over-year is largely driven by labor cost increases and further investments in our innovation pipeline and some further investments in our commercial engine as we increase our investments in some upcoming precision medicine and applications. Depreciation expense, which was about $3 million in the third quarter would be closer to $3.7 million in the fourth quarter from the increased investments in our facilities. Stock compensation expense, which was roughly $6 million in the third quarter will be roughly the same in the fourth quarter.
For adjusted EBITDA, the fourth quarter of 2023, we expect range of $42 million to $45 million. For the full-year of 2023, for adjusted EBITDA, we expect a range of $193 million to $196 million. Interest expense, which was nearly $7 million in the third quarter, is expected to be roughly $6.5 million in the fourth quarter of 2023, driven by the continued rise in interest rates, partially offset by good success we had in the third quarter, paying down our debt balances. We continue to focus on paying down debt to mitigate the impact of rising rates. We expect our non-GAAP tax rate to be about 18% in the fourth quarter of 2023, and we expect our non-GAAP tax rate to be approximately 16% for the full year of 2023, largely in line with 2022. Diluted weighted average shares outstanding will be approximately 36 million shares and adjusted diluted earnings per share, we expect a range of $0.59 to $0.66 in the fourth quarter.
But for the full year of 2023, adjusted earnings per share is now expected to be in the range of $2.98 and $3.05. Finally, we expect cash flows to stay strong in the fourth quarter as we continue to focus on our efforts of bringing down our inventory levels and from strong customer collections. In addition, our new Manchester, UK optical subsystem manufacturing facility and our new Czech Republic medical consumables manufacturing facility are both on track and scheduled to be completed on time. Despite some launch dates shifting slightly, we remain under increasing pressure from our customers to accelerate our readiness, which includes completing these two facilities and qualifying the production of our products for our customer product launches.
These facilities are expected to see the launch of significant new revenues tied to our second-generation smoke evacuation insufflators, new precision medicine products, and next-generation lithography-based applications. As always, this guidance does not assume any significant changes to foreign exchange rates. In summary, Novanta's performance in the third quarter of 2023 was solid and reflected excellent execution by our teams. We beat our own expectations for margin expansion, profit performance and cash flow. We saw continued growth in our medical end markets, which offset a growing softness in industrial markets. This dynamic was yet another testament to the diversification and resiliency of our business portfolio. Despite an increasing challenging interest rate environment and macroeconomic weakness, we are confident in our ability to navigate the short term and deliver on an accelerating secular growing strategy.
Overall, despite industrial capital spending environment in contraction territory for five quarters longer than historical down cycles, our business has held up reasonably well. While the economic climate is not expected to worsen nor improve significantly over the next couple of quarters, we do see our long-term growth prospects remaining strong and even accelerating on the back of exciting new product launches in the second half of 2024 and our exposure to high growth end markets in both the medical and advanced industrial applications. We remain very grateful for the outstanding performance of our employees and their efforts to help us be successful in a dynamic environment. We remain grateful to our customer's confidence and faith in our ability to deliver to their needs, the innovations they need to be successful.
We look forward to continuing to deliver on our commitments to our employees, our customers and our shareholders. This concludes the prepared remarks.
See also 15 Most Valuable Sports Companies in the World and 12 Best Most Active Stocks To Buy.
To continue reading the Q&A session, please click here.
